BindingDB logo
myBDB logout

Patent code US10329260

Compile Data Set for Download or QSAR

Found 302 hits of Enzyme Inhibition Constant Data   
Target/Host
(Institution)
LigandTarget/Host
Links
Ligand
Links
Trg + Lig
Links
Ki
nM
ΔG°
kJ/mole
IC50
nM
Kd
nM
EC50
nM
koff
s-1
kon
M-1s-1
pHTemp
°C
Plasma kallikrein


(Homo sapiens (Human))
BDBM417009
PNG
(1-(3-carbamimidoylphenyl)-N-(5-((+-)-3-cyclopropyl...)
Show SMILES CC(C)(C)[S@@](=O)NC(CCC1CC1)(c1cccnc1)c1ccc(F)c(NC(=O)c2cc(nn2-c2cccc(c2)C(N)=N)C(F)(F)F)c1
Show InChI InChI=1S/C33H35F4N7O2S/c1-31(2,3)47(46)43-32(14-13-20-9-10-20,23-7-5-15-40-19-23)22-11-12-25(34)26(17-22)41-30(45)27-18-28(33(35,36)37)42-44(27)24-8-4-6-21(16-24)29(38)39/h4-8,11-12,15-20,43H,9-10,13-14H2,1-3H3,(H3,38,39)(H,41,45)/t32?,47-/m1/s1
PDB

Reactome pathway

UniProtKB/SwissProt

antibodypedia
GoogleScholar
PC cid
PC sid
UniChem
US Patent
25.1n/an/an/an/an/an/an/an/a



BioCryst Pharmaceuticals, Inc.

US Patent


Assay Description
The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...


US Patent US10329260 (2019)


BindingDB Entry DOI: 10.7270/Q2R78HM5
More data for this
Ligand-Target Pair
Plasma kallikrein


(Homo sapiens (Human))
BDBM417020
PNG
(HCl salt of (+-)-1-(3-carbamimidoylphenyl)-N-(5-((...)
Show SMILES NC(=N)c1cccc(c1)-n1nc(cc1C(=O)Nc1cc(ccc1F)[C@@H](NCC1CC1)c1ccccc1)C(F)(F)F
Show InChI InChI=1S/C29H26F4N6O/c30-22-12-11-19(26(36-16-17-9-10-17)18-5-2-1-3-6-18)14-23(22)37-28(40)24-15-25(29(31,32)33)38-39(24)21-8-4-7-20(13-21)27(34)35/h1-8,11-15,17,26,36H,9-10,16H2,(H3,34,35)(H,37,40)/t26-/m0/s1
PDB

Reactome pathway

UniProtKB/SwissProt

antibodypedia
GoogleScholar
PC cid
PC sid
UniChem
US Patent
25.1n/an/an/an/an/an/an/an/a



BioCryst Pharmaceuticals, Inc.

US Patent


Assay Description
The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...


US Patent US10329260 (2019)


BindingDB Entry DOI: 10.7270/Q2R78HM5
More data for this
Ligand-Target Pair
Plasma kallikrein


(Homo sapiens (Human))
BDBM416742
PNG
(1-(3-(aminomethyl)phenyl)-N-(3-((cyclopropylmethyl...)
Show SMILES NCc1cccc(c1)-n1nc(cc1C(=O)Nc1cccc(C(NCC2CC2)c2ccccc2)c1F)C(F)(F)F
Show InChI InChI=1S/C29H27F4N5O/c30-26-22(27(35-17-18-12-13-18)20-7-2-1-3-8-20)10-5-11-23(26)36-28(39)24-15-25(29(31,32)33)37-38(24)21-9-4-6-19(14-21)16-34/h1-11,14-15,18,27,35H,12-13,16-17,34H2,(H,36,39)
PDB

Reactome pathway

UniProtKB/SwissProt

antibodypedia
GoogleScholar
PC cid
PC sid
UniChem
US Patent
25.1n/an/an/an/an/an/an/an/a



BioCryst Pharmaceuticals, Inc.

US Patent


Assay Description
The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...


US Patent US10329260 (2019)


BindingDB Entry DOI: 10.7270/Q2R78HM5
More data for this
Ligand-Target Pair
Plasma kallikrein


(Homo sapiens (Human))
BDBM416775
PNG
(1-(3-(aminomethyl)phenyl)-N-(3-((cyclopropylmethox...)
Show SMILES NCc1cccc(c1)-n1nc(cc1C(=O)Nc1cccc(c1)C(OCC1CC1)c1ccccc1)C(F)(F)F
Show InChI InChI=1S/C29H27F3N4O2/c30-29(31,32)26-16-25(36(35-26)24-11-4-6-20(14-24)17-33)28(37)34-23-10-5-9-22(15-23)27(38-18-19-12-13-19)21-7-2-1-3-8-21/h1-11,14-16,19,27H,12-13,17-18,33H2,(H,34,37)
PDB

Reactome pathway

UniProtKB/SwissProt

antibodypedia
GoogleScholar
PC cid
PC sid
UniChem
US Patent
25.1n/an/an/an/an/an/an/an/a



BioCryst Pharmaceuticals, Inc.

US Patent


Assay Description
The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...


US Patent US10329260 (2019)


BindingDB Entry DOI: 10.7270/Q2R78HM5
More data for this
Ligand-Target Pair
Plasma kallikrein


(Homo sapiens (Human))
BDBM416784
PNG
(1-(3-(aminomethyl)phenyl)-N-(5-((cyclopropylmethyl...)
Show SMILES NCc1cccc(c1)-n1nc(cc1C(=O)Nc1cc(ccc1F)C(NCC1CC1)c1cccnc1)C(F)(F)F
Show InChI InChI=1S/C28H26F4N6O/c29-22-9-8-19(26(35-15-17-6-7-17)20-4-2-10-34-16-20)12-23(22)36-27(39)24-13-25(28(30,31)32)37-38(24)21-5-1-3-18(11-21)14-33/h1-5,8-13,16-17,26,35H,6-7,14-15,33H2,(H,36,39)
PDB

Reactome pathway

UniProtKB/SwissProt

antibodypedia
GoogleScholar
PC cid
PC sid
UniChem
US Patent
25.1n/an/an/an/an/an/an/an/a



BioCryst Pharmaceuticals, Inc.

US Patent


Assay Description
The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...


US Patent US10329260 (2019)


BindingDB Entry DOI: 10.7270/Q2R78HM5
More data for this
Ligand-Target Pair
Plasma kallikrein


(Homo sapiens (Human))
BDBM416786
PNG
(2-(3-Aminomethyl-phenyl)-5-trifluoromethyl-2H-pyra...)
Show SMILES NCc1cccc(c1)-n1nc(cc1C(=O)Nc1cccc(c1)C(NCC1CC1)c1cccc2ccccc12)C(F)(F)F
Show InChI InChI=1S/C33H30F3N5O/c34-33(35,36)30-18-29(41(40-30)26-11-3-6-22(16-26)19-37)32(42)39-25-10-4-9-24(17-25)31(38-20-21-14-15-21)28-13-5-8-23-7-1-2-12-27(23)28/h1-13,16-18,21,31,38H,14-15,19-20,37H2,(H,39,42)
PDB

Reactome pathway

UniProtKB/SwissProt

antibodypedia
GoogleScholar
PC cid
PC sid
UniChem
US Patent
25.1n/an/an/an/an/an/an/an/a



BioCryst Pharmaceuticals, Inc.

US Patent


Assay Description
The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...


US Patent US10329260 (2019)


BindingDB Entry DOI: 10.7270/Q2R78HM5
More data for this
Ligand-Target Pair
Plasma kallikrein


(Homo sapiens (Human))
BDBM416812
PNG
(1-(3-(aminomethyl)phenyl)-N-(5-((cyclopropylmethyl...)
Show SMILES NCc1cccc(c1)-n1nc(cc1C(=O)Nc1cc(ccc1F)C(NCC1CC1)c1ccccn1)C(F)(F)F
Show InChI InChI=1S/C28H26F4N6O/c29-21-10-9-19(26(35-16-17-7-8-17)22-6-1-2-11-34-22)13-23(21)36-27(39)24-14-25(28(30,31)32)37-38(24)20-5-3-4-18(12-20)15-33/h1-6,9-14,17,26,35H,7-8,15-16,33H2,(H,36,39)
PDB

Reactome pathway

UniProtKB/SwissProt

antibodypedia
GoogleScholar
PC cid
PC sid
UniChem
US Patent
25.1n/an/an/an/an/an/an/an/a



BioCryst Pharmaceuticals, Inc.

US Patent


Assay Description
The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...


US Patent US10329260 (2019)


BindingDB Entry DOI: 10.7270/Q2R78HM5
More data for this
Ligand-Target Pair
Plasma kallikrein


(Homo sapiens (Human))
BDBM416873
PNG
(1-(3-(aminomethyl)phenyl)-N-(5-((4-carbamoylphenyl...)
Show SMILES NCc1cccc(c1)-n1nc(cc1C(=O)Nc1cc(ccc1F)C(NCC1CC1)c1ccc(cc1)C(N)=O)C(F)(F)F
Show InChI InChI=1S/C30H28F4N6O2/c31-23-11-10-21(27(37-16-17-4-5-17)19-6-8-20(9-7-19)28(36)41)13-24(23)38-29(42)25-14-26(30(32,33)34)39-40(25)22-3-1-2-18(12-22)15-35/h1-3,6-14,17,27,37H,4-5,15-16,35H2,(H2,36,41)(H,38,42)
PDB

Reactome pathway

UniProtKB/SwissProt

antibodypedia
GoogleScholar
PC cid
PC sid
UniChem
US Patent
25.1n/an/an/an/an/an/an/an/a



BioCryst Pharmaceuticals, Inc.

US Patent


Assay Description
The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...


US Patent US10329260 (2019)


BindingDB Entry DOI: 10.7270/Q2R78HM5
More data for this
Ligand-Target Pair
Plasma kallikrein


(Homo sapiens (Human))
BDBM416888
PNG
(1-(3-(aminomethyl)phenyl)-N-(3-(3-cyclopropyl-1-me...)
Show SMILES COC(CCC1CC1)(c1cccnc1)c1cccc(NC(=O)c2cc(nn2-c2cccc(CN)c2)C(F)(F)F)c1
Show InChI InChI=1S/C30H30F3N5O2/c1-40-29(13-12-20-10-11-20,23-7-4-14-35-19-23)22-6-3-8-24(16-22)36-28(39)26-17-27(30(31,32)33)37-38(26)25-9-2-5-21(15-25)18-34/h2-9,14-17,19-20H,10-13,18,34H2,1H3,(H,36,39)
PDB

Reactome pathway

UniProtKB/SwissProt

antibodypedia
GoogleScholar
PC cid
PC sid
UniChem
US Patent
25.1n/an/an/an/an/an/an/an/a



BioCryst Pharmaceuticals, Inc.

US Patent


Assay Description
The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...


US Patent US10329260 (2019)


BindingDB Entry DOI: 10.7270/Q2R78HM5
More data for this
Ligand-Target Pair
Plasma kallikrein


(Homo sapiens (Human))
BDBM416893
PNG
(1-(3-(aminomethyl)phenyl)-N-(3-(((cyclopropylmethy...)
Show SMILES NCc1cccc(c1)-n1nc(cc1C(=O)Nc1cccc(c1)C(NCC1CC1)c1ccc(F)cc1F)C(F)(F)F
Show InChI InChI=1S/C29H26F5N5O/c30-20-9-10-23(24(31)13-20)27(36-16-17-7-8-17)19-4-2-5-21(12-19)37-28(40)25-14-26(29(32,33)34)38-39(25)22-6-1-3-18(11-22)15-35/h1-6,9-14,17,27,36H,7-8,15-16,35H2,(H,37,40)
PDB

Reactome pathway

UniProtKB/SwissProt

antibodypedia
GoogleScholar
PC cid
PC sid
UniChem
US Patent
25.1n/an/an/an/an/an/an/an/a



BioCryst Pharmaceuticals, Inc.

US Patent


Assay Description
The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...


US Patent US10329260 (2019)


BindingDB Entry DOI: 10.7270/Q2R78HM5
More data for this
Ligand-Target Pair
Plasma kallikrein


(Homo sapiens (Human))
BDBM416906
PNG
(1-(3-(aminomethyl)phenyl)-N-(5-((cyclopropylmethyl...)
Show SMILES COc1ccc2ccccc2c1C(NCC1CC1)c1ccc(F)c(NC(=O)c2cc(nn2-c2cccc(CN)c2)C(F)(F)F)c1
Show InChI InChI=1S/C34H31F4N5O2/c1-45-29-14-12-22-6-2-3-8-25(22)31(29)32(40-19-20-9-10-20)23-11-13-26(35)27(16-23)41-33(44)28-17-30(34(36,37)38)42-43(28)24-7-4-5-21(15-24)18-39/h2-8,11-17,20,32,40H,9-10,18-19,39H2,1H3,(H,41,44)
PDB

Reactome pathway

UniProtKB/SwissProt

antibodypedia
GoogleScholar
PC cid
PC sid
UniChem
US Patent
25.1n/an/an/an/an/an/an/an/a



BioCryst Pharmaceuticals, Inc.

US Patent


Assay Description
The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...


US Patent US10329260 (2019)


BindingDB Entry DOI: 10.7270/Q2R78HM5
More data for this
Ligand-Target Pair
Plasma kallikrein


(Homo sapiens (Human))
BDBM416952
PNG
((+-)-1-(3-(aminomethyl)phenyl)-N-(5-((cyclopropylm...)
Show SMILES NCc1cccc(c1)-n1nc(cc1C(=O)Nc1cc(ccc1F)C(OCC1CC1)c1cccnc1)C(F)(F)F
Show InChI InChI=1S/C28H25F4N5O2/c29-22-9-8-19(26(39-16-17-6-7-17)20-4-2-10-34-15-20)12-23(22)35-27(38)24-13-25(28(30,31)32)36-37(24)21-5-1-3-18(11-21)14-33/h1-5,8-13,15,17,26H,6-7,14,16,33H2,(H,35,38)
PDB

Reactome pathway

UniProtKB/SwissProt

antibodypedia
GoogleScholar
PC cid
PC sid
UniChem
US Patent
25.1n/an/an/an/an/an/an/an/a



BioCryst Pharmaceuticals, Inc.

US Patent


Assay Description
The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...


US Patent US10329260 (2019)


BindingDB Entry DOI: 10.7270/Q2R78HM5
More data for this
Ligand-Target Pair
Plasma kallikrein


(Homo sapiens (Human))
BDBM416954
PNG
(1-(3-(aminomethyl)phenyl)-N-(5-(3-cyclopropyl-1-(2...)
Show SMILES NCc1cccc(c1)-n1nc(cc1C(=O)Nc1cc(ccc1F)C(CCC1CC1)N1C(=O)CCC1=O)C(F)(F)F
Show InChI InChI=1S/C28H27F4N5O3/c29-20-8-7-18(22(9-6-16-4-5-16)36-25(38)10-11-26(36)39)13-21(20)34-27(40)23-14-24(28(30,31)32)35-37(23)19-3-1-2-17(12-19)15-33/h1-3,7-8,12-14,16,22H,4-6,9-11,15,33H2,(H,34,40)
PDB

Reactome pathway

UniProtKB/SwissProt

antibodypedia
GoogleScholar
PC cid
PC sid
UniChem
US Patent
25.1n/an/an/an/an/an/an/an/a



BioCryst Pharmaceuticals, Inc.

US Patent


Assay Description
The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...


US Patent US10329260 (2019)


BindingDB Entry DOI: 10.7270/Q2R78HM5
More data for this
Ligand-Target Pair
Plasma kallikrein


(Homo sapiens (Human))
BDBM416955
PNG
((+-)-1-(3-(Aminomethyl)phenyl)-N-(3-((cyclopropylm...)
Show SMILES COc1ccc2ccccc2c1C(NCC1CC1)c1cccc(NC(=O)c2cc(nn2-c2cccc(CN)c2)C(F)(F)F)c1
Show InChI InChI=1S/C34H32F3N5O2/c1-44-29-15-14-23-7-2-3-11-27(23)31(29)32(39-20-21-12-13-21)24-8-5-9-25(17-24)40-33(43)28-18-30(34(35,36)37)41-42(28)26-10-4-6-22(16-26)19-38/h2-11,14-18,21,32,39H,12-13,19-20,38H2,1H3,(H,40,43)
PDB

Reactome pathway

UniProtKB/SwissProt

antibodypedia
GoogleScholar
PC cid
PC sid
UniChem
US Patent
25.1n/an/an/an/an/an/an/an/a



BioCryst Pharmaceuticals, Inc.

US Patent


Assay Description
The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...


US Patent US10329260 (2019)


BindingDB Entry DOI: 10.7270/Q2R78HM5
More data for this
Ligand-Target Pair
Plasma kallikrein


(Homo sapiens (Human))
BDBM416832
PNG
(1-(3-(aminomethyl)phenyl)-N-(3-((cyclopropylmethyl...)
Show SMILES CS(=O)(=O)c1ccccc1C(NCC1CC1)c1cccc(NC(=O)c2cc(nn2-c2cccc(CN)c2)C(F)(F)F)c1
Show InChI InChI=1S/C30H30F3N5O3S/c1-42(40,41)26-11-3-2-10-24(26)28(35-18-19-12-13-19)21-7-5-8-22(15-21)36-29(39)25-16-27(30(31,32)33)37-38(25)23-9-4-6-20(14-23)17-34/h2-11,14-16,19,28,35H,12-13,17-18,34H2,1H3,(H,36,39)
PDB

Reactome pathway

UniProtKB/SwissProt

antibodypedia
GoogleScholar
PC cid
PC sid
UniChem
US Patent
25.1n/an/an/an/an/an/an/an/a



BioCryst Pharmaceuticals, Inc.

US Patent


Assay Description
The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...


US Patent US10329260 (2019)


BindingDB Entry DOI: 10.7270/Q2R78HM5
More data for this
Ligand-Target Pair
Plasma kallikrein


(Homo sapiens (Human))
BDBM416833
PNG
(1-(3-(aminomethyl)phenyl)-N-(5-((4-(aminomethyl)ph...)
Show SMILES NCc1ccc(cc1)C(NCC1CC1)c1ccc(F)c(NC(=O)c2cc(nn2-c2cccc(CN)c2)C(F)(F)F)c1
Show InChI InChI=1S/C30H30F4N6O/c31-24-11-10-22(28(37-17-19-4-5-19)21-8-6-18(15-35)7-9-21)13-25(24)38-29(41)26-14-27(30(32,33)34)39-40(26)23-3-1-2-20(12-23)16-36/h1-3,6-14,19,28,37H,4-5,15-17,35-36H2,(H,38,41)
PDB

Reactome pathway

UniProtKB/SwissProt

antibodypedia
GoogleScholar
PC cid
PC sid
UniChem
US Patent
25.1n/an/an/an/an/an/an/an/a



BioCryst Pharmaceuticals, Inc.

US Patent


Assay Description
The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...


US Patent US10329260 (2019)


BindingDB Entry DOI: 10.7270/Q2R78HM5
More data for this
Ligand-Target Pair
Plasma kallikrein


(Homo sapiens (Human))
BDBM416837
PNG
(1-(3-(aminomethyl)phenyl)-N-(3-((cyclopropylmethyl...)
Show SMILES NCc1cccc(c1)-n1nc(cc1C(=O)Nc1cccc(c1)C(NCC1CC1)c1ccccc1O)C(F)(F)F
Show InChI InChI=1S/C29H28F3N5O2/c30-29(31,32)26-15-24(37(36-26)22-8-3-5-19(13-22)16-33)28(39)35-21-7-4-6-20(14-21)27(34-17-18-11-12-18)23-9-1-2-10-25(23)38/h1-10,13-15,18,27,34,38H,11-12,16-17,33H2,(H,35,39)
PDB

Reactome pathway

UniProtKB/SwissProt

antibodypedia
GoogleScholar
PC cid
PC sid
UniChem
US Patent
25.1n/an/an/an/an/an/an/an/a



BioCryst Pharmaceuticals, Inc.

US Patent


Assay Description
The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...


US Patent US10329260 (2019)


BindingDB Entry DOI: 10.7270/Q2R78HM5
More data for this
Ligand-Target Pair
Plasma kallikrein


(Homo sapiens (Human))
BDBM416853
PNG
(1-(3-(aminomethyl)phenyl)-N-(5-((3-aminophenyl)(cy...)
Show SMILES NCc1cccc(c1)-n1nc(cc1C(=O)Nc1cc(ccc1F)C(OCC1CC1)c1cccc(N)c1)C(F)(F)F
Show InChI InChI=1S/C29H27F4N5O2/c30-23-10-9-20(27(40-16-17-7-8-17)19-4-2-5-21(35)12-19)13-24(23)36-28(39)25-14-26(29(31,32)33)37-38(25)22-6-1-3-18(11-22)15-34/h1-6,9-14,17,27H,7-8,15-16,34-35H2,(H,36,39)
PDB

Reactome pathway

UniProtKB/SwissProt

antibodypedia
GoogleScholar
PC cid
PC sid
UniChem
US Patent
25.1n/an/an/an/an/an/an/an/a



BioCryst Pharmaceuticals, Inc.

US Patent


Assay Description
The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...


US Patent US10329260 (2019)


BindingDB Entry DOI: 10.7270/Q2R78HM5
More data for this
Ligand-Target Pair
Plasma kallikrein


(Homo sapiens (Human))
BDBM416855
PNG
(1-(3-(Aminomethyl)phenyl)-N-(3-((cyclopropylmethyl...)
Show SMILES Cc1cc(C(=O)Nc2cccc(c2)C(NCC2CC2)c2cc(O)ccc2O)n(n1)-c1cccc(CN)c1
Show InChI InChI=1S/C29H31N5O3/c1-18-12-26(34(33-18)23-7-2-4-20(13-23)16-30)29(37)32-22-6-3-5-21(14-22)28(31-17-19-8-9-19)25-15-24(35)10-11-27(25)36/h2-7,10-15,19,28,31,35-36H,8-9,16-17,30H2,1H3,(H,32,37)
PDB

Reactome pathway

UniProtKB/SwissProt

antibodypedia
GoogleScholar
PC cid
PC sid
UniChem
US Patent
25.1n/an/an/an/an/an/an/an/a



BioCryst Pharmaceuticals, Inc.

US Patent


Assay Description
The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...


US Patent US10329260 (2019)


BindingDB Entry DOI: 10.7270/Q2R78HM5
More data for this
Ligand-Target Pair
Plasma kallikrein


(Homo sapiens (Human))
BDBM417003
PNG
((+)-1-(3-carbamimidoylphenyl)-N-(5-((3-cyanophenyl...)
Show SMILES NC(=N)c1cccc(c1)-n1nc(cc1C(=O)Nc1cc(ccc1F)C(NCC1CC1)c1cccc(c1)C#N)C(F)(F)F
Show InChI InChI=1S/C30H25F4N7O/c31-23-10-9-20(27(38-16-17-7-8-17)19-4-1-3-18(11-19)15-35)13-24(23)39-29(42)25-14-26(30(32,33)34)40-41(25)22-6-2-5-21(12-22)28(36)37/h1-6,9-14,17,27,38H,7-8,16H2,(H3,36,37)(H,39,42)
PDB

Reactome pathway

UniProtKB/SwissProt

antibodypedia
GoogleScholar
PC cid
PC sid
UniChem
US Patent
25.1n/an/an/an/an/an/an/an/a



BioCryst Pharmaceuticals, Inc.

US Patent


Assay Description
The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...


US Patent US10329260 (2019)


BindingDB Entry DOI: 10.7270/Q2R78HM5
More data for this
Ligand-Target Pair
Plasma kallikrein


(Homo sapiens (Human))
BDBM416926
PNG
((+)-1-(3-(aminomethyl)phenyl)-N-(5-((3-cyanophenyl...)
Show SMILES NCc1cccc(c1)-n1nc(cc1C(=O)Nc1cc(ccc1F)C(NCC1CC1)c1cccc(c1)C#N)C(F)(F)F
Show InChI InChI=1S/C30H26F4N6O/c31-24-10-9-22(28(37-17-18-7-8-18)21-5-1-3-19(11-21)15-35)13-25(24)38-29(41)26-14-27(30(32,33)34)39-40(26)23-6-2-4-20(12-23)16-36/h1-6,9-14,18,28,37H,7-8,16-17,36H2,(H,38,41)
PDB

Reactome pathway

UniProtKB/SwissProt

antibodypedia
GoogleScholar
PC cid
PC sid
UniChem
US Patent
25.1n/an/an/an/an/an/an/an/a



BioCryst Pharmaceuticals, Inc.

US Patent


Assay Description
The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...


US Patent US10329260 (2019)


BindingDB Entry DOI: 10.7270/Q2R78HM5
More data for this
Ligand-Target Pair
Plasma kallikrein


(Homo sapiens (Human))
BDBM416932
PNG
((+-)-1-(3-(aminomethyl)phenyl)-N-(5-(3-cyclopropyl...)
Show SMILES NCc1cccc(c1)-n1nc(cc1C(=O)Nc1cc(ccc1F)C(O)(CCC1CC1)c1ccccn1)C(F)(F)F
Show InChI InChI=1S/C29H27F4N5O2/c30-22-10-9-20(28(40,12-11-18-7-8-18)25-6-1-2-13-35-25)15-23(22)36-27(39)24-16-26(29(31,32)33)37-38(24)21-5-3-4-19(14-21)17-34/h1-6,9-10,13-16,18,40H,7-8,11-12,17,34H2,(H,36,39)
PDB

Reactome pathway

UniProtKB/SwissProt

antibodypedia
GoogleScholar
PC cid
PC sid
UniChem
US Patent
25.1n/an/an/an/an/an/an/an/a



BioCryst Pharmaceuticals, Inc.

US Patent


Assay Description
The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...


US Patent US10329260 (2019)


BindingDB Entry DOI: 10.7270/Q2R78HM5
More data for this
Ligand-Target Pair
Plasma kallikrein


(Homo sapiens (Human))
BDBM416935
PNG
((+)-1-(3-(aminomethyl)phenyl)-N-(5-(3-cyclopropyl-...)
Show SMILES NCc1cccc(c1)-n1nc(cc1C(=O)Nc1cc(ccc1F)C(O)(CCC1CC1)c1ccccn1)C(F)(F)F
Show InChI InChI=1S/C29H27F4N5O2/c30-22-10-9-20(28(40,12-11-18-7-8-18)25-6-1-2-13-35-25)15-23(22)36-27(39)24-16-26(29(31,32)33)37-38(24)21-5-3-4-19(14-21)17-34/h1-6,9-10,13-16,18,40H,7-8,11-12,17,34H2,(H,36,39)
PDB

Reactome pathway

UniProtKB/SwissProt

antibodypedia
GoogleScholar
PC cid
PC sid
UniChem
US Patent
25.1n/an/an/an/an/an/an/an/a



BioCryst Pharmaceuticals, Inc.

US Patent


Assay Description
The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...


US Patent US10329260 (2019)


BindingDB Entry DOI: 10.7270/Q2R78HM5
More data for this
Ligand-Target Pair
Plasma kallikrein


(Homo sapiens (Human))
BDBM416936
PNG
(1-(3-(aminomethyl)phenyl)-N-(3-(3-cyclopropyl-1-(2...)
Show SMILES NCc1cccc(c1)-n1nc(cc1C(=O)Nc1cccc(c1)C(CCC1CC1)N1CCCC1=O)C(F)(F)F
Show InChI InChI=1S/C28H30F3N5O2/c29-28(30,31)25-16-24(36(34-25)22-7-1-4-19(14-22)17-32)27(38)33-21-6-2-5-20(15-21)23(12-11-18-9-10-18)35-13-3-8-26(35)37/h1-2,4-7,14-16,18,23H,3,8-13,17,32H2,(H,33,38)
PDB

Reactome pathway

UniProtKB/SwissProt

antibodypedia
GoogleScholar
PC cid
PC sid
UniChem
US Patent
25.1n/an/an/an/an/an/an/an/a



BioCryst Pharmaceuticals, Inc.

US Patent


Assay Description
The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...


US Patent US10329260 (2019)


BindingDB Entry DOI: 10.7270/Q2R78HM5
More data for this
Ligand-Target Pair
Plasma kallikrein


(Homo sapiens (Human))
BDBM416730
PNG
(1-(3-(aminomethyl)phenyl)-N-(3-(3-cyclopropyl-1-ph...)
Show SMILES NCc1cccc(c1)-n1nc(cc1C(=O)Nc1cccc(c1)C(CCC1CC1)c1ccccc1)C(F)(F)F
Show InChI InChI=1S/C30H29F3N4O/c31-30(32,33)28-18-27(37(36-28)25-11-4-6-21(16-25)19-34)29(38)35-24-10-5-9-23(17-24)26(15-14-20-12-13-20)22-7-2-1-3-8-22/h1-11,16-18,20,26H,12-15,19,34H2,(H,35,38)
PDB

Reactome pathway

UniProtKB/SwissProt

antibodypedia
GoogleScholar
PC cid
PC sid
UniChem
US Patent
25.1n/an/an/an/an/an/an/an/a



BioCryst Pharmaceuticals, Inc.

US Patent


Assay Description
The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...


US Patent US10329260 (2019)


BindingDB Entry DOI: 10.7270/Q2R78HM5
More data for this
Ligand-Target Pair
Plasma kallikrein


(Homo sapiens (Human))
BDBM416733
PNG
(1-(3-(Aminomethyl)phenyl)-N-(3-(((cyclopropylmethy...)
Show SMILES NCc1cccc(c1)-n1nc(cc1C(=O)Nc1cccc(c1)C(NCC1CC1)c1cccnc1)C(F)(F)F
Show InChI InChI=1S/C28H27F3N6O/c29-28(30,31)25-14-24(37(36-25)23-8-1-4-19(12-23)15-32)27(38)35-22-7-2-5-20(13-22)26(34-16-18-9-10-18)21-6-3-11-33-17-21/h1-8,11-14,17-18,26,34H,9-10,15-16,32H2,(H,35,38)
PDB

Reactome pathway

UniProtKB/SwissProt

antibodypedia
GoogleScholar
PC cid
PC sid
UniChem
US Patent
25.1n/an/an/an/an/an/an/an/a



BioCryst Pharmaceuticals, Inc.

US Patent


Assay Description
The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...


US Patent US10329260 (2019)


BindingDB Entry DOI: 10.7270/Q2R78HM5
More data for this
Ligand-Target Pair
Plasma kallikrein


(Homo sapiens (Human))
BDBM417012
PNG
((+)-N-(5-(1-amino-1-(4-cyanophenyl)-3-cyclopropylp...)
Show SMILES NC(=N)c1cccc(c1)-n1nc(cc1C(=O)Nc1cc(ccc1F)C(N)(CCC1CC1)c1ccc(cc1)C#N)C(F)(F)F
Show InChI InChI=1S/C31H27F4N7O/c32-24-11-10-22(30(39,13-12-18-4-5-18)21-8-6-19(17-36)7-9-21)15-25(24)40-29(43)26-16-27(31(33,34)35)41-42(26)23-3-1-2-20(14-23)28(37)38/h1-3,6-11,14-16,18H,4-5,12-13,39H2,(H3,37,38)(H,40,43)
PDB

Reactome pathway

UniProtKB/SwissProt

antibodypedia
GoogleScholar
PC cid
PC sid
UniChem
US Patent
25.1n/an/an/an/an/an/an/an/a



BioCryst Pharmaceuticals, Inc.

US Patent


Assay Description
The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...


US Patent US10329260 (2019)


BindingDB Entry DOI: 10.7270/Q2R78HM5
More data for this
Ligand-Target Pair
Plasma kallikrein


(Homo sapiens (Human))
BDBM417023
PNG
((+)-N-(5-(1-amino-1-(4-carbamoylphenyl)-3-cyclopro...)
Show SMILES NCc1cccc(c1)-n1nc(cc1C(=O)Nc1cc(ccc1F)C(N)(CCC1CC1)c1ccc(cc1)C(N)=O)C(F)(F)F
Show InChI InChI=1S/C31H30F4N6O2/c32-24-11-10-22(30(38,13-12-18-4-5-18)21-8-6-20(7-9-21)28(37)42)15-25(24)39-29(43)26-16-27(31(33,34)35)40-41(26)23-3-1-2-19(14-23)17-36/h1-3,6-11,14-16,18H,4-5,12-13,17,36,38H2,(H2,37,42)(H,39,43)
PDB

Reactome pathway

UniProtKB/SwissProt

antibodypedia
GoogleScholar
PC cid
PC sid
UniChem
US Patent
25.1n/an/an/an/an/an/an/an/a



BioCryst Pharmaceuticals, Inc.

US Patent


Assay Description
The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...


US Patent US10329260 (2019)


BindingDB Entry DOI: 10.7270/Q2R78HM5
More data for this
Ligand-Target Pair
Plasma kallikrein


(Homo sapiens (Human))
BDBM417024
PNG
((+)-N-(5-(1-amino-3-cyclopropyl-1-(pyridin-4-yl)pr...)
Show SMILES NCc1cccc(c1)-n1nc(cc1C(=O)Nc1cc(ccc1F)C(N)(CCC1CC1)c1ccncc1)C(F)(F)F
Show InChI InChI=1S/C29H28F4N6O/c30-23-7-6-21(28(35,11-8-18-4-5-18)20-9-12-36-13-10-20)15-24(23)37-27(40)25-16-26(29(31,32)33)38-39(25)22-3-1-2-19(14-22)17-34/h1-3,6-7,9-10,12-16,18H,4-5,8,11,17,34-35H2,(H,37,40)
PDB

Reactome pathway

UniProtKB/SwissProt

antibodypedia
GoogleScholar
PC cid
PC sid
UniChem
US Patent
25.1n/an/an/an/an/an/an/an/a



BioCryst Pharmaceuticals, Inc.

US Patent


Assay Description
The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...


US Patent US10329260 (2019)


BindingDB Entry DOI: 10.7270/Q2R78HM5
More data for this
Ligand-Target Pair
Plasma kallikrein


(Homo sapiens (Human))
BDBM417026
PNG
((+-)-1-(3-(aminomethyl)phenyl)-N5-(5-((cyclopropyl...)
Show SMILES NCc1cccc(c1)-n1nc(cc1C(=O)Nc1cc(ccc1F)C(NCC1CC1)c1ccccc1)C(N)=O
Show InChI InChI=1S/C29H29FN6O2/c30-23-12-11-21(27(33-17-18-9-10-18)20-6-2-1-3-7-20)14-24(23)34-29(38)26-15-25(28(32)37)35-36(26)22-8-4-5-19(13-22)16-31/h1-8,11-15,18,27,33H,9-10,16-17,31H2,(H2,32,37)(H,34,38)
PDB

Reactome pathway

UniProtKB/SwissProt

antibodypedia
GoogleScholar
PC cid
PC sid
UniChem
US Patent
25.1n/an/an/an/an/an/an/an/a



BioCryst Pharmaceuticals, Inc.

US Patent


Assay Description
The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...


US Patent US10329260 (2019)


BindingDB Entry DOI: 10.7270/Q2R78HM5
More data for this
Ligand-Target Pair
Plasma kallikrein


(Homo sapiens (Human))
BDBM417032
PNG
(1-(1-aminoisoquinolin-7-yl)-N-(5-(3-cyclopropyl-1-...)
Show SMILES Nc1nccc2ccc(cc12)-n1nc(cc1C(=O)Nc1cc(ccc1F)C(CCC1CC1)n1ccc(=O)[nH]c1=O)C(F)(F)F
PDB

Reactome pathway

UniProtKB/SwissProt

antibodypedia
GoogleScholar
PC cid
PC sid
UniChem
US Patent
25.1n/an/an/an/an/an/an/an/a



BioCryst Pharmaceuticals, Inc.

US Patent


Assay Description
The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...


US Patent US10329260 (2019)


BindingDB Entry DOI: 10.7270/Q2R78HM5
More data for this
Ligand-Target Pair
Plasma kallikrein


(Homo sapiens (Human))
BDBM416748
PNG
(1-(3-(aminomethyl)phenyl)-N-(3-((cyclopropylmethyl...)
Show SMILES NCc1cccc(c1)-n1nc(cc1C(=O)Nc1cccc(c1)C(NCC1CC1)c1ccccn1)C(F)(F)F
Show InChI InChI=1S/C28H27F3N6O/c29-28(30,31)25-15-24(37(36-25)22-8-3-5-19(13-22)16-32)27(38)35-21-7-4-6-20(14-21)26(34-17-18-10-11-18)23-9-1-2-12-33-23/h1-9,12-15,18,26,34H,10-11,16-17,32H2,(H,35,38)
PDB

Reactome pathway

UniProtKB/SwissProt

antibodypedia
GoogleScholar
PC cid
PC sid
UniChem
US Patent
25.1n/an/an/an/an/an/an/an/a



BioCryst Pharmaceuticals, Inc.

US Patent


Assay Description
The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...


US Patent US10329260 (2019)


BindingDB Entry DOI: 10.7270/Q2R78HM5
More data for this
Ligand-Target Pair
Plasma kallikrein


(Homo sapiens (Human))
BDBM416787
PNG
(1-(3-(aminomethyl)phenyl)-N-(3-cyclopropyl-5-((cyc...)
Show SMILES NCc1cccc(c1)-n1nc(cc1C(=O)Nc1cc(Cc2ccccc2NCC2CC2)cc(c1)C1CC1)C(F)(F)F
Show InChI InChI=1S/C32H32F3N5O/c33-32(34,35)30-17-29(40(39-30)27-6-3-4-21(15-27)18-36)31(41)38-26-14-22(13-25(16-26)23-10-11-23)12-24-5-1-2-7-28(24)37-19-20-8-9-20/h1-7,13-17,20,23,37H,8-12,18-19,36H2,(H,38,41)
PDB

Reactome pathway

UniProtKB/SwissProt

antibodypedia
GoogleScholar
PC cid
PC sid
UniChem
US Patent
25.1n/an/an/an/an/an/an/an/a



BioCryst Pharmaceuticals, Inc.

US Patent


Assay Description
The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...


US Patent US10329260 (2019)


BindingDB Entry DOI: 10.7270/Q2R78HM5
More data for this
Ligand-Target Pair
Plasma kallikrein


(Homo sapiens (Human))
BDBM416798
PNG
(1-(3-(aminomethyl)phenyl)-N-(3-((cyclopropylmethyl...)
Show SMILES CS(=O)(=O)c1cccc(c1)C(NCC1CC1)c1cccc(NC(=O)c2cc(nn2-c2cccc(CN)c2)C(F)(F)F)c1
Show InChI InChI=1S/C30H30F3N5O3S/c1-42(40,41)25-10-4-7-22(15-25)28(35-18-19-11-12-19)21-6-3-8-23(14-21)36-29(39)26-16-27(30(31,32)33)37-38(26)24-9-2-5-20(13-24)17-34/h2-10,13-16,19,28,35H,11-12,17-18,34H2,1H3,(H,36,39)
PDB

Reactome pathway

UniProtKB/SwissProt

antibodypedia
GoogleScholar
PC cid
PC sid
UniChem
US Patent
25.1n/an/an/an/an/an/an/an/a



BioCryst Pharmaceuticals, Inc.

US Patent


Assay Description
The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...


US Patent US10329260 (2019)


BindingDB Entry DOI: 10.7270/Q2R78HM5
More data for this
Ligand-Target Pair
Plasma kallikrein


(Homo sapiens (Human))
BDBM416809
PNG
(1-(3-(aminomethyl)phenyl)-N-(3-(2-(cyclopropylamin...)
Show SMILES NCc1cccc(c1)-n1nc(cc1C(=O)Nc1cccc(c1)C(O)(CNC1CC1)c1ccccc1)C(F)(F)F
Show InChI InChI=1S/C29H28F3N5O2/c30-29(31,32)26-16-25(37(36-26)24-11-4-6-19(14-24)17-33)27(38)35-23-10-5-9-21(15-23)28(39,18-34-22-12-13-22)20-7-2-1-3-8-20/h1-11,14-16,22,34,39H,12-13,17-18,33H2,(H,35,38)
PDB

Reactome pathway

UniProtKB/SwissProt

antibodypedia
GoogleScholar
PC cid
PC sid
UniChem
US Patent
25.1n/an/an/an/an/an/an/an/a



BioCryst Pharmaceuticals, Inc.

US Patent


Assay Description
The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...


US Patent US10329260 (2019)


BindingDB Entry DOI: 10.7270/Q2R78HM5
More data for this
Ligand-Target Pair
Plasma kallikrein


(Homo sapiens (Human))
BDBM416823
PNG
(1-(3-(aminomethyl)phenyl)-N-(3-(((cyclopropylmethy...)
Show SMILES CC(C)c1ccc(cc1)C(NCC1CC1)c1cccc(NC(=O)c2cc(nn2-c2cccc(CN)c2)C(F)(F)F)c1
Show InChI InChI=1S/C32H34F3N5O/c1-20(2)23-11-13-24(14-12-23)30(37-19-21-9-10-21)25-6-4-7-26(16-25)38-31(41)28-17-29(32(33,34)35)39-40(28)27-8-3-5-22(15-27)18-36/h3-8,11-17,20-21,30,37H,9-10,18-19,36H2,1-2H3,(H,38,41)
PDB

Reactome pathway

UniProtKB/SwissProt

antibodypedia
GoogleScholar
PC cid
PC sid
UniChem
US Patent
25.1n/an/an/an/an/an/an/an/a



BioCryst Pharmaceuticals, Inc.

US Patent


Assay Description
The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...


US Patent US10329260 (2019)


BindingDB Entry DOI: 10.7270/Q2R78HM5
More data for this
Ligand-Target Pair
Plasma kallikrein


(Homo sapiens (Human))
BDBM416885
PNG
(1-(3-(aminomethyl)phenyl)-N-(5-((3-(aminomethyl)ph...)
Show SMILES NCc1cccc(c1)C(NCC1CC1)c1ccc(F)c(NC(=O)c2cc(nn2-c2cccc(CN)c2)C(F)(F)F)c1
Show InChI InChI=1S/C30H30F4N6O/c31-24-10-9-22(28(37-17-18-7-8-18)21-5-1-3-19(11-21)15-35)13-25(24)38-29(41)26-14-27(30(32,33)34)39-40(26)23-6-2-4-20(12-23)16-36/h1-6,9-14,18,28,37H,7-8,15-17,35-36H2,(H,38,41)
PDB

Reactome pathway

UniProtKB/SwissProt

antibodypedia
GoogleScholar
PC cid
PC sid
UniChem
US Patent
25.1n/an/an/an/an/an/an/an/a



BioCryst Pharmaceuticals, Inc.

US Patent


Assay Description
The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...


US Patent US10329260 (2019)


BindingDB Entry DOI: 10.7270/Q2R78HM5
More data for this
Ligand-Target Pair
Plasma kallikrein


(Homo sapiens (Human))
BDBM416891
PNG
(1-(3-(aminomethyl)phenyl)-N-(5-((3-cyanophenyl)(cy...)
Show SMILES NCc1cccc(c1)-n1nc(cc1C(=O)Nc1cc(ccc1F)C(NCC1CC1)c1cccc(c1)C#N)C(F)(F)F
Show InChI InChI=1S/C30H26F4N6O/c31-24-10-9-22(28(37-17-18-7-8-18)21-5-1-3-19(11-21)15-35)13-25(24)38-29(41)26-14-27(30(32,33)34)39-40(26)23-6-2-4-20(12-23)16-36/h1-6,9-14,18,28,37H,7-8,16-17,36H2,(H,38,41)
PDB

Reactome pathway

UniProtKB/SwissProt

antibodypedia
GoogleScholar
PC cid
PC sid
UniChem
US Patent
25.1n/an/an/an/an/an/an/an/a



BioCryst Pharmaceuticals, Inc.

US Patent


Assay Description
The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...


US Patent US10329260 (2019)


BindingDB Entry DOI: 10.7270/Q2R78HM5
More data for this
Ligand-Target Pair
Plasma kallikrein


(Homo sapiens (Human))
BDBM416913
PNG
((+)-1-(3-(aminomethyl)phenyl)-N-(3-((cyclopropylme...)
Show SMILES NCc1cccc(c1)-n1nc(cc1C(=O)Nc1cccc(c1)C(OCC1CC1)c1ccccc1)C(F)(F)F
Show InChI InChI=1S/C29H27F3N4O2/c30-29(31,32)26-16-25(36(35-26)24-11-4-6-20(14-24)17-33)28(37)34-23-10-5-9-22(15-23)27(38-18-19-12-13-19)21-7-2-1-3-8-21/h1-11,14-16,19,27H,12-13,17-18,33H2,(H,34,37)
PDB

Reactome pathway

UniProtKB/SwissProt

antibodypedia
GoogleScholar
PC cid
PC sid
UniChem
US Patent
25.1n/an/an/an/an/an/an/an/a



BioCryst Pharmaceuticals, Inc.

US Patent


Assay Description
The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...


US Patent US10329260 (2019)


BindingDB Entry DOI: 10.7270/Q2R78HM5
More data for this
Ligand-Target Pair
Plasma kallikrein


(Homo sapiens (Human))
BDBM416916
PNG
((+-)-1-(3-(aminomethyl)phenyl)-N-(3-((cyclopropylm...)
Show SMILES NCc1cccc(c1)-n1nc(cc1C(=O)Nc1cccc(c1)C(OCC1CC1)c1ccccc1)C(F)(F)F
Show InChI InChI=1S/C29H27F3N4O2/c30-29(31,32)26-16-25(36(35-26)24-11-4-6-20(14-24)17-33)28(37)34-23-10-5-9-22(15-23)27(38-18-19-12-13-19)21-7-2-1-3-8-21/h1-11,14-16,19,27H,12-13,17-18,33H2,(H,34,37)
PDB

Reactome pathway

UniProtKB/SwissProt

antibodypedia
GoogleScholar
PC cid
PC sid
UniChem
US Patent
25.1n/an/an/an/an/an/an/an/a



BioCryst Pharmaceuticals, Inc.

US Patent


Assay Description
The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...


US Patent US10329260 (2019)


BindingDB Entry DOI: 10.7270/Q2R78HM5
More data for this
Ligand-Target Pair
Plasma kallikrein


(Homo sapiens (Human))
BDBM416917
PNG
((+)-1-(3-(aminomethyl)phenyl)-N-(5-(((cyclopropylm...)
Show SMILES NCc1cccc(c1)-n1nc(cc1C(=O)Nc1cc(ccc1F)C(NCC1CC1)c1ccccc1)C(F)(F)F
Show InChI InChI=1S/C29H27F4N5O/c30-23-12-11-21(27(35-17-18-9-10-18)20-6-2-1-3-7-20)14-24(23)36-28(39)25-15-26(29(31,32)33)37-38(25)22-8-4-5-19(13-22)16-34/h1-8,11-15,18,27,35H,9-10,16-17,34H2,(H,36,39)
PDB

Reactome pathway

UniProtKB/SwissProt

antibodypedia
GoogleScholar
PC cid
PC sid
UniChem
US Patent
25.1n/an/an/an/an/an/an/an/a



BioCryst Pharmaceuticals, Inc.

US Patent


Assay Description
The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...


US Patent US10329260 (2019)


BindingDB Entry DOI: 10.7270/Q2R78HM5
More data for this
Ligand-Target Pair
Plasma kallikrein


(Homo sapiens (Human))
BDBM416919
PNG
((+)-1-(3-(aminomethyl)phenyl)-N-(3-((4-aminophenyl...)
Show SMILES NCc1cccc(c1)-n1nc(cc1C(=O)Nc1cccc(c1)C(NCC1CC1)c1ccc(N)cc1)C(F)(F)F
Show InChI InChI=1S/C29H29F3N6O/c30-29(31,32)26-15-25(38(37-26)24-6-1-3-19(13-24)16-33)28(39)36-23-5-2-4-21(14-23)27(35-17-18-7-8-18)20-9-11-22(34)12-10-20/h1-6,9-15,18,27,35H,7-8,16-17,33-34H2,(H,36,39)
PDB

Reactome pathway

UniProtKB/SwissProt

antibodypedia
GoogleScholar
PC cid
PC sid
UniChem
US Patent
25.1n/an/an/an/an/an/an/an/a



BioCryst Pharmaceuticals, Inc.

US Patent


Assay Description
The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...


US Patent US10329260 (2019)


BindingDB Entry DOI: 10.7270/Q2R78HM5
More data for this
Ligand-Target Pair
Plasma kallikrein


(Homo sapiens (Human))
BDBM416947
PNG
((+-)-1-(3-(aminomethyl)phenyl)-N-(5-((cyclopropylm...)
Show SMILES COc1ccc2ccccc2c1C(NCC1CC1)c1ccc(F)c(NC(=O)c2cc(nn2-c2cccc(CN)c2)C(F)(F)F)c1
Show InChI InChI=1S/C34H31F4N5O2/c1-45-29-14-12-22-6-2-3-8-25(22)31(29)32(40-19-20-9-10-20)23-11-13-26(35)27(16-23)41-33(44)28-17-30(34(36,37)38)42-43(28)24-7-4-5-21(15-24)18-39/h2-8,11-17,20,32,40H,9-10,18-19,39H2,1H3,(H,41,44)
PDB

Reactome pathway

UniProtKB/SwissProt

antibodypedia
GoogleScholar
PC cid
PC sid
UniChem
US Patent
25.1n/an/an/an/an/an/an/an/a



BioCryst Pharmaceuticals, Inc.

US Patent


Assay Description
The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...


US Patent US10329260 (2019)


BindingDB Entry DOI: 10.7270/Q2R78HM5
More data for this
Ligand-Target Pair
Plasma kallikrein


(Homo sapiens (Human))
BDBM416845
PNG
(1-(3-(aminomethyl)phenyl)-N-(5-(((cyclopropylmethy...)
Show SMILES COc1ccc(cc1)C(NCC1CC1)c1ccc(F)c(NC(=O)c2cc(nn2-c2cccc(CN)c2)C(F)(F)F)c1
Show InChI InChI=1S/C30H29F4N5O2/c1-41-23-10-7-20(8-11-23)28(36-17-18-5-6-18)21-9-12-24(31)25(14-21)37-29(40)26-15-27(30(32,33)34)38-39(26)22-4-2-3-19(13-22)16-35/h2-4,7-15,18,28,36H,5-6,16-17,35H2,1H3,(H,37,40)
PDB

Reactome pathway

UniProtKB/SwissProt

antibodypedia
GoogleScholar
PC cid
PC sid
UniChem
US Patent
25.1n/an/an/an/an/an/an/an/a



BioCryst Pharmaceuticals, Inc.

US Patent


Assay Description
The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...


US Patent US10329260 (2019)


BindingDB Entry DOI: 10.7270/Q2R78HM5
More data for this
Ligand-Target Pair
Plasma kallikrein


(Homo sapiens (Human))
BDBM416846
PNG
(1-(3-(Aminomethyl)phenyl)-N-(3-((3-(benzyloxy)phen...)
Show SMILES NCc1cccc(c1)-n1nc(cc1C(=O)Nc1cccc(CN(CC2CC2)c2cccc(OCc3ccccc3)c2)c1)C(F)(F)F
Show InChI InChI=1S/C36H34F3N5O2/c37-36(38,39)34-20-33(44(42-34)31-13-5-9-27(18-31)21-40)35(45)41-29-11-4-10-28(17-29)23-43(22-25-15-16-25)30-12-6-14-32(19-30)46-24-26-7-2-1-3-8-26/h1-14,17-20,25H,15-16,21-24,40H2,(H,41,45)
PDB

Reactome pathway

UniProtKB/SwissProt

antibodypedia
GoogleScholar
PC cid
PC sid
UniChem
US Patent
25.1n/an/an/an/an/an/an/an/a



BioCryst Pharmaceuticals, Inc.

US Patent


Assay Description
The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...


US Patent US10329260 (2019)


BindingDB Entry DOI: 10.7270/Q2R78HM5
More data for this
Ligand-Target Pair
Plasma kallikrein


(Homo sapiens (Human))
BDBM416848
PNG
(1-(3-(aminomethyl)phenyl)-N-(3-((cyclopropylmethyl...)
Show SMILES Cc1cc(C(=O)Nc2cccc(c2)C(NCC2CC2)c2ccccc2)n(n1)-c1cccc(CN)c1
Show InChI InChI=1S/C29H31N5O/c1-20-15-27(34(33-20)26-12-5-7-22(16-26)18-30)29(35)32-25-11-6-10-24(17-25)28(31-19-21-13-14-21)23-8-3-2-4-9-23/h2-12,15-17,21,28,31H,13-14,18-19,30H2,1H3,(H,32,35)
PDB

Reactome pathway

UniProtKB/SwissProt

antibodypedia
GoogleScholar
PC cid
PC sid
UniChem
US Patent
25.1n/an/an/an/an/an/an/an/a



BioCryst Pharmaceuticals, Inc.

US Patent


Assay Description
The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...


US Patent US10329260 (2019)


BindingDB Entry DOI: 10.7270/Q2R78HM5
More data for this
Ligand-Target Pair
Plasma kallikrein


(Homo sapiens (Human))
BDBM416962
PNG
((+-)-1-(3-(aminomethyl)phenyl)-N-(5-((cyclopropylm...)
Show SMILES NCc1cccc(c1)-n1nc(cc1C(=O)Nc1cc(ccc1F)C(NCC1CC1)c1ccccc1O)C(F)(F)F
Show InChI InChI=1S/C29H27F4N5O2/c30-22-11-10-19(27(35-16-17-8-9-17)21-6-1-2-7-25(21)39)13-23(22)36-28(40)24-14-26(29(31,32)33)37-38(24)20-5-3-4-18(12-20)15-34/h1-7,10-14,17,27,35,39H,8-9,15-16,34H2,(H,36,40)
PDB

Reactome pathway

UniProtKB/SwissProt

antibodypedia
GoogleScholar
PC cid
PC sid
UniChem
US Patent
25.1n/an/an/an/an/an/an/an/a



BioCryst Pharmaceuticals, Inc.

US Patent


Assay Description
The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...


US Patent US10329260 (2019)


BindingDB Entry DOI: 10.7270/Q2R78HM5
More data for this
Ligand-Target Pair
Plasma kallikrein


(Homo sapiens (Human))
BDBM416965
PNG
((+)-1-(3-(aminomethyl)phenyl)-N-(5-((cyclopropylme...)
Show SMILES NCc1cccc(c1)-n1nc(cc1C(=O)Nc1cc(ccc1F)C(NCC1CC1)c1ccccc1O)C(F)(F)F
Show InChI InChI=1S/C29H27F4N5O2/c30-22-11-10-19(27(35-16-17-8-9-17)21-6-1-2-7-25(21)39)13-23(22)36-28(40)24-14-26(29(31,32)33)37-38(24)20-5-3-4-18(12-20)15-34/h1-7,10-14,17,27,35,39H,8-9,15-16,34H2,(H,36,40)
PDB

Reactome pathway

UniProtKB/SwissProt

antibodypedia
GoogleScholar
PC cid
PC sid
UniChem
US Patent
25.1n/an/an/an/an/an/an/an/a



BioCryst Pharmaceuticals, Inc.

US Patent


Assay Description
The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...


US Patent US10329260 (2019)


BindingDB Entry DOI: 10.7270/Q2R78HM5
More data for this
Ligand-Target Pair
Plasma kallikrein


(Homo sapiens (Human))
BDBM416970
PNG
((+-)-1-(3-(aminomethyl)phenyl)-N-(3-((cyclopropylm...)
Show SMILES NCc1cccc(c1)-n1nc(cc1C(=O)Nc1cccc(c1)C(NCC1CC1)c1ccccc1O)C(F)(F)F
Show InChI InChI=1S/C29H28F3N5O2/c30-29(31,32)26-15-24(37(36-26)22-8-3-5-19(13-22)16-33)28(39)35-21-7-4-6-20(14-21)27(34-17-18-11-12-18)23-9-1-2-10-25(23)38/h1-10,13-15,18,27,34,38H,11-12,16-17,33H2,(H,35,39)
PDB

Reactome pathway

UniProtKB/SwissProt

antibodypedia
GoogleScholar
PC cid
PC sid
UniChem
US Patent
25.1n/an/an/an/an/an/an/an/a



BioCryst Pharmaceuticals, Inc.

US Patent


Assay Description
The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...


US Patent US10329260 (2019)


BindingDB Entry DOI: 10.7270/Q2R78HM5
More data for this
Ligand-Target Pair
Plasma kallikrein


(Homo sapiens (Human))
BDBM416998
PNG
((+)-N-(5-(1-amino-1-(4-cyanophenyl)-3-cyclopropylp...)
Show SMILES Nc1nccc2ccc(cc12)-n1nc(cc1C(=O)Nc1cc(ccc1F)C(N)(CCC1CC1)c1ccc(cc1)C#N)C(F)(F)F
Show InChI InChI=1S/C33H27F4N7O/c34-26-10-8-23(32(40,13-11-19-1-2-19)22-6-3-20(18-38)4-7-22)15-27(26)42-31(45)28-17-29(33(35,36)37)43-44(28)24-9-5-21-12-14-41-30(39)25(21)16-24/h3-10,12,14-17,19H,1-2,11,13,40H2,(H2,39,41)(H,42,45)
PDB

Reactome pathway

UniProtKB/SwissProt

antibodypedia
GoogleScholar
PC cid
PC sid
UniChem
US Patent
25.1n/an/an/an/an/an/an/an/a



BioCryst Pharmaceuticals, Inc.

US Patent


Assay Description
The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...


US Patent US10329260 (2019)


BindingDB Entry DOI: 10.7270/Q2R78HM5
More data for this
Ligand-Target Pair
Displayed 1 to 50 (of 302 total )  |  Next  |  Last  >>
* indicates data uncertainty>20%